Surveillance procedures for patients with cervical carcinoma a review of the literature

International Journal of Gynecological Cancer

Volumn 19, Issue 2, 2009, Pages 194-201

  Zanagnolo, Vanna ^a   Ming, Lucas ^a   Gadducci, Angiolo ^b   Maggino, Tiziano ^c   Sartori, Enrico ^d   Zola, Paolo ^e   Landoni, Fabio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

Cervical cancer recurrence; Computed tomography; Fdg positron emission tomography computed tomography; Follow up; Magnetic resonance imaging

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ANESTHESIA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; EARLY DIAGNOSIS; FEASIBILITY STUDY; FOLLOW UP; FRACTURE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HYSTERECTOMY; IMAGING SYSTEM; LOBECTOMY; LUNG FIBROSIS; LUNG METASTASIS; LYMPH NODE; LYMPH NODE DISSECTION; MEDICAL PRACTICE; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAPANICOLAOU TEST; PARAAORTIC LYMPH NODE; PHYSICAL EXAMINATION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY; UNITED KINGDOM; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VAGINA CYTOLOGY; FEMALE; TUMOR RECURRENCE; UTERINE CERVIX TUMOR; VAGINA SMEAR;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 65649134344     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e31819c9ffd     Document Type: Review

References (59)

1. Bodurka-Bevers D, Morris M, Eifel PJ, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000;78:187-193.
2. Kosary CL, Schiffman MH, Trimble EL. Cervix uteri. In: Miller BA, Ries LAG, Hankey BF, et al, eds. SEER Cancer Statistic Review. Bethesda, MD: US Department of Health and Human Services; 1993: 1973-1990.
3. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
4. Olaitan A, Murdoch J, Anderson R, et al. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. Int J Gynecol Cancer. 2001;11:349-353.
5. Lim KC, Howells RE, Evans AS. The role of clinical follow up in early stage cervical cancer in South Wales. BJOG. 2004;111:1444-1448.
6. DiSaia PJ, Creasman WT. Clinical Gynecologic Oncology. 6th ed. St Louis, MO: Mosby; 2002:53-95.
7. Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy, I: A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67: 2776-2785.
8. Burghardt E. Surgical Gynecologic Oncology. New York, NY: Thieme Medical Publishers, Inc.; 1993:185-322.
9. Duyn A, Van Eijkeren M, Kenter G, et al. Recurrent cervical cancer: detection and prognosis. Acta Obstet Gynecol Scand. 2002;81:351-355.
10. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. 25th Volume of the FIGO Annual Report on the Results of Treatment of Gynecological Cancer. Int J Gynaecol Obstet. 2003;83 (Suppl 1): 41-78.
11. Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of the uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 1995;31:703-716.
12. Gerdin E, Cnattingius S, Johnson P, et al. Prognostic factors and relapse patterns in early-stage cervical carcinoma after brachytherapy and radical hysterectomy. Gynecol Oncol. 1994;53:314-319.
13. Larson DM, Copeland LJ, Malone JM Jr, et al. Diagnosis of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol. 1988; 71:6-9.
14. Ansink A, de Barros Lopes A, Naik R, et al. Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol. 1996;103:1156-1158.
15. Kew FM, Cruickshank DJ. Routine follow-up after treatment for a gynecological cancer: a survey of practice. Int J Gynecol Cancer. 2006;16:380-384.
16. Barnhill D, O'Connor D, Farley J, et al. Clinical surveillance of gynecologic cancer patients. Gynecol Oncol. 1992;46:275-280.
17. Zola P, Fuso L, Mazzola S, et al. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis. Gynecol Oncol. 2007; 107 (1 Suppl 1): S150-154.
18. Soisson AP, Geszler G, Soper JT, et al. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol. 1990;76:106-109.
19. Chien CR, Ting LL, Hsieh CY, et al. Post-radiation Pap smear for Chinese patients with cervical cancer: a ten-year follow-up. Eur J Gynaecol Oncol. 2005;26:619-622.
20. Injumpa N, Suprasert P, Srisomboon J, et al. Limited value of vaginal cytology in detecting recurrent disease after radical hysterectomy for early stage cervical carcinoma. Asian Pac J Cancer Prev. 2006;7:656-658.
21. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer. 1977;40:1621-1628.
22. Chan YM, Ng TY, Ngan HY, et al. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol. 2002;84:7-11.
23. Roijer E, de Bruijn HW, Dahlén U, et al. Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients. Tumour Biol. 2006;27:142-152.
24. Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169-173.
25. Juang CM, Wang PH, Yen MS, et al. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2000;76:103-106.
26. Esajas MD, Duk JM, de Bruijn HW, et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer. J Clin Oncol. 2001;19:3960-3966.
27. Dreyer G, Snyman L, Mount A, et al. Management of recurrent cervical cancer. Best Pract Res Clin Obstet Gynecol. 2006;19:631-644.
28. Hricak H, Powell CB, Yu KK, et al. Invasive cervical carcinoma: role of MR imaging in pretreatment work-up-cost minimization and diagnostic efficacy analysis. Radiology. 1996;198:403-409.
29. Imachi M, Tsukamoto N, Matsuyama T, et al. Pulmonary metastasis from carcinoma of the uterine cervix. Gynecol Oncol. 1989;33: 189-192.
30. Barter JF, Soong SJ, Hatch KD, et al. Diagnosis and treatment of pulmonary metastases from cervical carcinoma. Gynecol Oncol. 1990;38:347-351.
31. Jeong YY, Kang HK, Chung TW, et al. Uterine cervical carcinoma after therapy: CT and MR imaging findings. Radiographics. 2003;23: 969-981.
32. Dooms GC, Hricak H, Crooks LE, et al. Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology. 1984;153: 719-728.
33. Schwartz LB, Pangeas E, Lange R, et al. Female pelvis: impact of MR imaging on treatment decisions and net cost analysis. Radiology. 1994;192:55-60.
34. Weber TM, Sostman HD, Spritzer CE, et al. Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology. 1995;194:135-139.
35. Blomqvist L, Holm T, Göranson H, et al. MR imaging, CT and CEA scintigraphy in the diagnosis of local recurrence of rectal carcinoma. Acta Radiol. 1996;37:779-784.
36. Yamashita Y, Harada M, Torashima M, et al. Dynamic MR imaging of recurrent postoperative cervical cancer. J Magn Reson Imaging. 1996;6:167-171.
37. Kim SH, Han MC. Invasion of the urinary bladder by uterine cervical carcinoma: evaluation with MR imaging. AJR Am J Roentgenol. 1997;168:393-397.
38. Yu KH, Hricak H, Subak LL, et al. Preoperative staging of cervical carcinoma: phase array coil fast spin-echo versus body coil spin-echo T2-weighted MR imaging. AJR Am J Roentgenol. 1998;171:707-711.
39. Hricak HM, Akin O. Imaging cancer of the cervix: an update from Women's Imaging: strategies for clinical practice. Categorical Course Syllabus. ARRS. 2004.
40. Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology. 1990;175:45-51.
41. Choi JI, Kim SH, Seong CK, et al. Recurrent uterine cervical carcinoma: spectrum of imaging findings. Korean J Radiol. 2000;1:198-207.
42. Yang WT, Lam WW, Yu MY, et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol. 2000;175:759-766.
43. Chung HH, Kim SK, Kim TH, et al. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol. 2006;103:165-170.
44. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004;94:212-216.
45. Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys. 2003;55:907-913.
46. 18F-FDG PET in patients with cervical cancer. J Nucl Med. 2003;44: 347-352.
47. Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer. 2004;101:164-171.
48. Sakurai H, Suzuki Y, Nonaka T, et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy-tumor volume and FDG uptake value. Gynecol Oncol. 2006;100:601-607.
49. Yen TC, Lai CH, Ma SY, et al. Comparative benefits and limitations of (18) F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging. 2006;33:1399-1407.
50. Chung HH, Jo H, Kang WJ, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol. 2007;104:529-534.
51. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363-1378.
52. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000:41:1369-1379.
53. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44:1200-1209.
54. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
55. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003;23:315-340.
56. Amit A, Beck D, Lowenstein L, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol. 2006;100: 65-69.
57. NCCN Clinical Practice Guidelines in Oncology - Cervical Cancer (V.2.2006). Available at: http://www.nccn.org/professionals/physician-gls/PDF/ cervical.pdf.
58. American College of Obstetricians and Gynaecologists (ACOG). Diagnosis and treatment of cervical carcinomas. Washington (DC): American College of Obstetricians and Gynaecologists (ACOG). 2002 May 13 (ACOG practice bulletin; no. 35). Available at: http://www.guideline.gov/summary/summary.aspxss= 15&doc-id=3983&nbr=3122.
59. Linee guida SIGO in Ginecologia Oncologica. Available at: http://www.sigo.it.